Galecto Inc (GLTO) - Total Assets
Based on the latest financial reports, Galecto Inc (GLTO) holds total assets worth $535.44 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Galecto Inc - Total Assets Trend (2018–2025)
This chart illustrates how Galecto Inc's total assets have evolved over time, based on quarterly financial data. Also see GLTO market cap overview for the company's overall valuation and market capitalisation.
Galecto Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Galecto Inc's total assets of $535.44 Million consist of 100.0% current assets and 0.0% non-current assets. Review GLTO liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.9% |
| Accounts Receivable | $899.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Galecto Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Galecto Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galecto Inc's current assets represent 100.0% of total assets in 2025, an increase from 99.6% in 2018.
- Cash Position: Cash and equivalents constituted 98.9% of total assets in 2025, up from 88.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Galecto Inc Competitors by Total Assets
Key competitors of Galecto Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $715.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
USA | $470.43 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
|
CureVac NV
F:5CV
|
Germany | €1.14 Billion |
Galecto Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.48 | 9.62 | 22.65 |
| Quick Ratio | 22.48 | 9.62 | 21.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $511.60 Million | $13.37 Million | $102.95 Million |
Galecto Inc - Advanced Valuation Insights
This section examines the relationship between Galecto Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 163.79 |
| Latest Market Cap to Assets Ratio | 5.65 |
| Asset Growth Rate (YoY) | 1420.7% |
| Total Assets | $260.53 Million |
| Market Capitalization | $1.47 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Galecto Inc's assets at a significant premium (5.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Galecto Inc's assets grew by 1420.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Galecto Inc (2018–2025)
The table below shows the annual total assets of Galecto Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $260.53 Million | +1420.70% |
| 2024-12-31 | $17.13 Million | -55.18% |
| 2023-12-31 | $38.23 Million | -47.77% |
| 2022-12-31 | $73.19 Million | -40.12% |
| 2021-12-31 | $122.22 Million | -28.78% |
| 2020-12-31 | $171.60 Million | +203.12% |
| 2019-12-31 | $56.61 Million | +61.26% |
| 2018-12-31 | $35.10 Million | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more